STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Stat News • 2/5/2026 – 3/9/2026
Summary
No summary yet.
Advertisement
Cluster Activity
1
2
4
2
1
1
2026-02-052026-03-09
Lindy Score Breakdown (V4.2)
4d
Age
3
Sources
from cluster
107
Hours Since Seen
Final Score10/100
CategoryAntiLindy
StatusActive
Recency Multiplier21% (0.5^107/48)
Hero EligibleYes
Story Timeline
- 2026-02-05
- 2026-02-06
- 2026-02-07
- 2026-02-09
- 2026-02-11
- 2026-03-09STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales (current)
Score BreakdownRisk 35
Source Reputation: Low-trust source (4/20 pts)
Consensus: Emerging consensus: 3 sources
Age: 4 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Same Story from 11 sources
STAT+: Hims is in the crosshairs. Is a crackdown coming for compounding?
Stat News • 1+ months
STAT+: Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says
Stat News • 1+ months
STAT+: Novo Nordisk sues Hims & Hers for infringing on a key Wegovy patent
Stat News • 1+ months
STAT+: Hims & Hers will stop selling compounded version of Novo’s obesity pill
Stat News • 1+ months
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Financial Times • 1+ months
HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy - statnews.com
Stat News • 1+ months
STAT+: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy
Stat News • 1+ months
STAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and more
Stat News • 1+ months
US health company launches weight-loss pill that Novo Nordisk calls an 'untested knockoff'
Euronews • 1+ months
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
Stat News • 1+ months
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more
Stat News • 2 days ago
STAT+: FDA approves leucovorin for rare disorder without trial data
Stat News • 2 days ago
STAT+: FDA launches unified system for adverse event reports
Stat News • 1 day ago
STAT+: Trump is getting more credit than Biden for efforts to lower drug prices
Stat News • Today
STAT+: This billionaire wants to make science better, especially for AI
Stat News • 2 days ago
STAT+: White House says it’s ‘done’ with vaccines. MAHA begs to differ
Stat News • Today
STAT+: Cancer cells can ‘barf’ proteins onto their cell surface. That may create new targets for immunotherapies
Stat News • 1 day ago
Analysis of Medicare data shows who mental health providers treat over telehealth
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more
Stat News • Today
STAT+: Grail CEO steps down after trial setback
Stat News • Today